---
document_datetime: 2025-07-25 11:16:47
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ondexxya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ondexxya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.8227904
conversion_datetime: 2025-12-20 18:58:15.276304
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ondexxya

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                       |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------|
| II/0044              | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information based on the final results from study 18-513 (ANNEXA-I), listed as a specific obligation in the Annex II; this is a phase 4 randomised controlled trial to investigate the efficacy and safety of | 19/06/2025                          |                                             | SmPC, Annex II, Labelling and PL | For more information, please refer to the Summary of Product Characteristics. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | andexanet alfa versus usual care in patients with acute intracranial haemorrhage taking apixaban, rivaroxaban or edoxaban. The Annex II and Package Leaflet are updated accordingly. The updated RMP version 4.0, succession number 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to bring it in line with the latest QRD template version 10.3. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0049    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 30/01/2025 | 04/04/2025 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the re-newal of the conditional MA for Ondexxya, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0046/G | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a                                                                                                                                                                                                                                                            | 27/03/2025 | n/a        | B.I.b.2.d (Type II) - To replace the current Generation 1 process specific method for Host Cell Protein (HCP) for release testing of Ondexxya (andexanet alfa) active substance with a Generation 2 process specific polyclonal antibody assay (Gen 2 HCP assay). This type II variation is to fulfil a Quality Recommendation (PAM, REC002 from iMAA).                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                    |            |            | B.I.b.1.b (Type IB) - To tighten the release and shelf-life active substance specification limits for HCP from ≤ 10.0 μg HCP/mg protein to ≤ 6.9 μg HCP/mg protein.                                                                                                                                                                                                                                                                                                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10764 /202404 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                                                              | 28/11/2024 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0048/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile) | 17/09/2024 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10764 /202310 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                                                              | 16/05/2024 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0041              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                   | 25/01/2024 | 11/03/2024 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Ondexxya, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0043/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                        | 18/12/2023 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0042             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                              | 11/12/2023 | 11/03/2024 | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10764 /202304 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                                                     | 30/11/2023 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0033             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                | 26/04/2023 | 08/06/2023 | SmPC, Annex II and PL | The SmPC and package leaflet were updated based on results of a PK and PK/PD Analysis aiming at confirming the approved posology to fulfil Specific Obligations (SOB) 001 and 003. This is a PK and PK/PD Analysis of Intravenously Administered Andexanet after dosing to steady state with a factor Xa inhibitor, rivaroxaban or apixaban, in healthy subjects and patients who have acute major bleeding. The posology should in general be maintained, but SmPC and package leaflet were updated to reflect that no evidence-based recommendation for andexanet treatment for 'unknown' DOAC treatment-modality is available from clinical data or M&S. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                      |            |            |                        | Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                  | 30/05/2023 | 11/03/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10764 /202210 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                         | 12/05/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0034              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                              | 23/02/2023 | 24/04/2023 |                        | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Ondexxya, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0038/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 15/03/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0035             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                    | 23/02/2023 | 24/04/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IAIN/0037           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/02/2023   | 24/04/2023   | Annex II and PL        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| PSUSA/10764 /202204 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 01/12/2022   | n/a          |                        | PRAC Recommendation - maintenance |
| IB/0029/G           | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of | 04/07/2022   | n/a          |                        |                                   |
| T/0031              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 29/04/2022   | 07/06/2022   | SmPC, Labelling and PL |                                   |
| IB/0030/G           | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                               | 12/05/2022   | n/a          |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0025    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/01/2022 | 29/04/2022 |                       | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Ondexxya, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| II/0022/G | This was an application for a group of variations. Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on the final study report from study 14-505 (ANNEXA-4). This is a prospective, open-label study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/04/2022 | 07/06/2022 | SmPC, Annex II and PL | The recommended dose regimen of Ondexxya is based on the dose of the direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) the patient is taking at the time of anticoagulation reversal, as well as on the time since the patient's last dose of the direct factor Xa (FXa) inhibitor                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | of andexanet alfa in patients receiving a factor Xa inhibitor who have acute major bleeding to confirm safety and efficacy in patients with acute major bleeds. The package leaflet was updated accordingly. In addition, the marketing authorisation holder took the opportunity to implement editorial changes in the SmPC and PL. The Annex II (SOBs) has been updated. The revised RMP version 2.5 has also been submitted. Change to the summary of pharmacovigilance system due to change in QPPV. C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     | (apixaban or rivaroxaban). Measurement of baseline anti- FXa-level should support the clinical decision of starting treatment (if level is available in an acceptable timely frame). For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0028/G | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                     | 14/03/2022 | n/a |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0026             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/12/2021   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10764 /202104 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 02/12/2021   | n/a   | PRAC Recommendation - maintenance |
| IB/0024/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement | 11/10/2021   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                           |            |            |                       |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| II/0020/G           | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes | 07/10/2021 | n/a        |                       |                                   |
| II/0003             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                         | 16/09/2021 | 29/04/2022 | Annex II              |                                   |
| PSUSA/10764 /202010 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                                                                                                                                          | 10/06/2021 | n/a        |                       | PRAC Recommendation - maintenance |
| II/0009/G           | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                | 20/05/2021 | 29/04/2022 | SmPC, Annex II and PL |                                   |
| IAIN/0021           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                    | 20/04/2021 | n/a        |                       |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0019             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                           | 31/03/2021   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0015              | Renewal of the marketing authorisation.                                                                                                                                                                                                | 10/12/2020   | 19/02/2021 |                        | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Ondexxya, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IAIN/0018           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 09/02/2021   | 29/04/2022 | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| T/0016              | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 19/11/2020   | 07/01/2021 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10764 /202004 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                           | 26/11/2020   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0011             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                      | 15/10/2020   | 16/11/2020 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0012/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.b.4 - Stability of FP - Extension of the shelf life of the finished product - Based on extrapolation of stability data not in accordance with ICH/VICH guidelines   | 03/09/2020   | 16/11/2020   | SmPC   |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|-----------------------------------|
| IB/0013             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/06/2020   | 16/11/2020   | SmPC   |                                   |
| PSUSA/10764 /201910 | Periodic Safety Update EU Single assessment - andexanet alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/05/2020   | n/a          |        | PRAC Recommendation - maintenance |
| II/0007             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                    | 17/04/2020   | n/a          |        |                                   |
| IB/0006/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/04/2020   | n/a          |        |                                   |

<div style=\"page-break-after: always\"></div>

|         | change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                   | A.5.b - Administrative   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|--------------------------|
| R/0004  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                | 30/01/2020 | 01/04/2020 | Annex II          |                          |
| IB/0005 | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                             | 16/12/2019 | n/a        |                   |                          |
| II/0002 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                          | 12/12/2019 | 01/04/2020 | SmPC and Annex II |                          |
|         | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                 | 05/07/2019 | 01/04/2020 | Annex II and PL   | IAIN/0001                |